drugset
drugset / Trial / NCT05546151

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

NCT05546151 ↗

Phase 1 Completed 24 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of multiple ascending oral doses of BMS-986322 in healthy participants of Japanese descent.

Timeline

Start
2022-09-28
Primary completion
2023-04-07
Completion
2023-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject LOMECITINIB Small molecule — Oral

Indications

No indication recorded.